Pioneering Project for Pharmaceutics – Vifor Pharma and the University of Basel are Jointly Establishing the World’s First Research Professorship for Nanopharmaceutical and Regulatory Science
May 26, 2019
(AETOS Wire) -- Nanopharmaceutics promises ground-breaking innovation in the development of medicines:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190526005014/en/
- The Vifor Pharma Group is endowing two professorships for Nanopharmaceutical and Regulatory"...
Progress review on foundation works of King Abdullah Medical City
May 22, 2019
Arabian Gulf University President Dr Khalid Abdulrahman Al Ohaly held a coordination meeting with Ministry of works, Municipalities Affairs & Urban Planning Undersecretary Eng. Ahmed Abdulaziz Al Khayyat to follow up on the foundation works of King Abdullah Medical City. The event took place at the Ministry premises in the presence of several engineers from the Ministry as well as representatives from the companies concerned with constructing the project. Dr Al Ohaly began the meeting by highlighting the fruitful collaboration"...
ResMed Study Finds CPAP Adherence Improved by Remote Monitoring, Self-Monitoring across 3 Countries
May 22, 2019
Remote monitoring and patient self-monitoring can drive CPAP adherence for people with sleep apnea, according to research presented by ResMed (NYSE: RMD) (ASX: RMD) at the American Thoracic Society’s 2019 ATS International Conference.
Average adherence to PAP (positive airway pressure), the gold standard for treating sleep apnea, is approximately 50 percent when using legacy technology with no cloud connectivity or remote monitoring capabilities."...
New Study Evaluates Ability of Masimo SpHb® (Noninvasive Hemoglobin) to Estimate Timing for Invasive Measurement to Detect Anemia During Surgery
May 21, 2019
(AETOS Wire) -- Masimo (NASDAQ: MASI) announced today the results of a study published in BMC Anesthesiology in which clinicians at Peking Union Medical College in Beijing evaluated the ability of noninvasive and continuous hemoglobin monitoring with Masimo SpHb® to help clincians estimate when to conduct invasive hemoglobin measurement to detect possible anemia in patients undergoing spine or cytoreductive surgery.1 Noting that because of the “invasive, time-consuming and intermittent” nature of invasive blood sampling, clincians often forgo these “objective indications” when making transfusion decisions during surgery, Dr. Tang and colleagues sought to determine whether noninvasive, continuous hemoglobin monitoring could aid clinicians in estimating when it might be appropriate to perform an invasive measurement. They enrolled 69 adult patients scheduled for......
Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD1
May 20, 2019
- Results of pivotal Phase III SENSCIS® trial published today in the New England Journal of Medicine (NEJM) and presented at the American Thoracic Society Conference in Dallas, USA
- Interstitial lung disease (ILD) is a key driver of mortality in people living with systemic sclerosis (SSc) – also known as scleroderma – and the absence of approved treatment options constitutes a high unmet need2,3
- FDA grants priority review to application for regulatory approval for nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD)
...
Age, Gender, Disease Severity Impact Adherence to Long-Term PAP Therapy More Than Previously Thought
May 20, 2019
(AETOS Wire) -- ResMed (NYSE: RMD, ASX: RMD) today revealed several demographic and clinical factors affect adherence to PAP (positive airway pressure) therapy, according to a study it presented at the American Thoracic Society's ATS 2019 International Conference.
The study found significant differences in one-year adherence between people of different ages and disease severity levels:
Takeda to Showcase Growing Pipeline and Diversified Portfolio of Oncology Products at Upcoming Scientific Congresses
May 20, 2019
(AETOS Wire) -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) today announced that the company will present data at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 31-June 4 in Chicago and the 24th Congress of the European Hematology Association (EHA), June 13-16 in Amsterdam. “We look forward to presenting data at ASCO and EHA that illustrate the continued progress of our portfolio in both clinical research and real-world settings in solid tumors and blood cancers,” said Phil Rowlands, Ph.D., Head, Oncology Therapeutic Area Unit, Takeda. “These data demonstrate our continued commitment to the discovery, development and delivery of medicines for patients with cancers.” At ASCO, Takeda will present data from both its lung portfolio and hematology portfolio. Results from a Phase 1/2 first-in-human, open-label, multicenter......
New Exploratory Data from VARSITY, First Head-to-Head Ulcerative Colitis Biologic Study Which Demonstrated Superiority of Vedolizumab to Adalimumab in Clinical Remission at Week 52, Presented at 2019 Digestive Disease Week®
May 20, 2019
(AETOS Wire)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced further results from the Phase 3b head-to-head VARSITY study, which demonstrated that the gut-selective biologic vedolizumab (Entyvio®) was superior to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira®) in achieving clinical remission* at week 52 in patients with moderately to severely active ulcerative colitis (UC).1 New exploratory data showed that a greater proportion of patients receiving vedolizumab intravenous (IV) achieved clinical response** at week 14 compared to those treated with adalimumab subcutaneous (SC), 67.1% vs. 45.9% respectively. A separation between the treatment groups was seen as early as week 6, favoring vedolizumab. These results were announced in a Distinguished Abstract Plenary Lecture Presentation at the 2019......
HRH Premier congratulated by Health Ministry Undersecretary
May 19, 2019
Manama, May 18 (BNA): His Royal Highness Prime Minister Prince Khalifa bin Salman Al Khalifa received a cable of congratulations from Health Ministry Undersecretary Dr. Walid bin Khalifa Al Mena on being chosen and honoured as a “World Leader” by the World Health Organisation (WHO).
Dr. Al Mena extended deepest congratulations to HRH the Prime Minister on the WHO honour, the first of its kind in the organisation’s history, describing it as an international recognition of HRH the Premier’s"...
Bahrain PM to get WHO global honour
May 18, 2019
The World Health Organisation (WHO) said it will honour the Premier for his visionary leadership that has made Bahrain’s health services a role model for other countries.
HRH Prime Minister Prince Khalifa bin Salman Al Khalifa will become the first world leader to be bestowed such an honour by the UN’s health watchdog.
He will be honoured at a ceremony at the UN Palace in Geneva on Monday in the presence of heads of states and governments as well as health ministers from the WHO’s"...
